• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

被认为有害的配体效率指标。

Ligand efficiency metrics considered harmful.

作者信息

Kenny Peter W, Leitão Andrei, Montanari Carlos A

机构信息

Grupo de em Química Medicinal do IQSC/USP - NEQUIMED, Instituto de Química de São Carlos, Universidade de São Paulo, Av. Trabalhador Sancarlense, 400, São Carlos, SP, 13566-590, Brazil,

出版信息

J Comput Aided Mol Des. 2014 Jul;28(7):699-710. doi: 10.1007/s10822-014-9757-8. Epub 2014 Jun 5.

DOI:10.1007/s10822-014-9757-8
PMID:24899110
Abstract

Ligand efficiency metrics are used in drug discovery to normalize biological activity or affinity with respect to physicochemical properties such as lipophilicity and molecular size. This Perspective provides an overview of ligand efficiency metrics and summarizes thermodynamics of protein-ligand binding. Different classes of ligand efficiency metric are critically examined and the study concludes with suggestions for alternative ways to account for physicochemical properties when prioritizing and optimizing leads.

摘要

配体效率指标在药物发现中用于根据亲脂性和分子大小等物理化学性质对生物活性或亲和力进行归一化。本观点概述了配体效率指标,并总结了蛋白质-配体结合的热力学。对不同类别的配体效率指标进行了批判性审视,研究最后针对在先导化合物的优先级排序和优化过程中考虑物理化学性质的替代方法提出了建议。

相似文献

1
Ligand efficiency metrics considered harmful.被认为有害的配体效率指标。
J Comput Aided Mol Des. 2014 Jul;28(7):699-710. doi: 10.1007/s10822-014-9757-8. Epub 2014 Jun 5.
2
The role of ligand efficiency metrics in drug discovery.配体效率指标在药物发现中的作用。
Nat Rev Drug Discov. 2014 Feb;13(2):105-21. doi: 10.1038/nrd4163.
3
Group Additivity in Ligand Binding Affinity: An Alternative Approach to Ligand Efficiency.配体结合亲和力的加和性:一种评估配体效率的替代方法。
J Chem Inf Model. 2017 Dec 26;57(12):3086-3093. doi: 10.1021/acs.jcim.7b00381. Epub 2017 Nov 16.
4
Binding thermodynamics discriminates fragments from druglike compounds: a thermodynamic description of fragment-based drug discovery.结合热力学区分片段与类药物化合物:基于片段的药物发现的热力学描述
Drug Discov Today. 2017 Apr;22(4):681-689. doi: 10.1016/j.drudis.2016.11.019. Epub 2016 Dec 1.
5
The impact of binding thermodynamics on medicinal chemistry optimizations.结合热力学对药物化学优化的影响。
Future Med Chem. 2015;7(10):1285-303. doi: 10.4155/fmc.15.63.
6
Thermodynamic profiling for fragment-based lead discovery and optimization.基于片段的药物发现和优化的热力学分析。
Expert Opin Drug Discov. 2020 Jan;15(1):117-129. doi: 10.1080/17460441.2020.1691166. Epub 2019 Nov 19.
7
The nature of ligand efficiency.配体效率的本质。
J Cheminform. 2019 Jan 31;11(1):8. doi: 10.1186/s13321-019-0330-2.
8
Practical application of ligand efficiency metrics in lead optimisation.配体效率指标在先导优化中的实际应用。
Bioorg Med Chem. 2018 Jul 15;26(11):3006-3015. doi: 10.1016/j.bmc.2018.04.004. Epub 2018 Apr 5.
9
Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.通过设计改进候选药物:关注物理化学性质,以改善化合物处置和安全性。
Chem Res Toxicol. 2011 Sep 19;24(9):1420-56. doi: 10.1021/tx200211v. Epub 2011 Jul 26.
10
A look at ligand binding thermodynamics in drug discovery.药物发现中的配体结合热力学研究
Expert Opin Drug Discov. 2017 Apr;12(4):363-377. doi: 10.1080/17460441.2017.1297418. Epub 2017 Mar 1.

引用本文的文献

1
2-Alkyl-Substituted-4-Amino-Thieno[2,3-]Pyrimidines: Anti-Proliferative Properties to In Vitro Breast Cancer Models.2- 烷基取代-4-氨基噻吩并[2,3-d]嘧啶类化合物:体外乳腺癌模型的抗增殖活性。
Molecules. 2023 Aug 30;28(17):6347. doi: 10.3390/molecules28176347.
2
Rational Design and Synthesis of New Selective COX-2 Inhibitors with In Vivo PGE2-Lowering Activity by Tethering Benzenesulfonamide and 1,2,3-Triazole Pharmacophores to Some NSAIDs.通过将苯磺酰胺和1,2,3-三唑药效基团连接到某些非甾体抗炎药上,合理设计并合成具有体内降低PGE2活性的新型选择性COX-2抑制剂
Pharmaceuticals (Basel). 2022 Sep 20;15(10):1165. doi: 10.3390/ph15101165.
3

本文引用的文献

1
QSAR Analysis Involving Assay Results Which are only Known to be Greater Than, or Less Than Some Cut-off Limit.涉及仅已知大于或小于某个截止限度的测定结果的定量构效关系分析。
Mol Inform. 2010 Dec 17;29(12):845-52. doi: 10.1002/minf.201000074. Epub 2010 Nov 29.
2
Best Practices for QSAR Model Development, Validation, and Exploitation.定量构效关系(QSAR)模型开发、验证及应用的最佳实践
Mol Inform. 2010 Jul 12;29(6-7):476-88. doi: 10.1002/minf.201000061. Epub 2010 Jul 6.
3
Validity of ligand efficiency metrics.配体效率指标的有效性。
Forces Driving a Magic Bullet to Its Target: Revisiting the Role of Thermodynamics in Drug Design, Development, and Optimization.
推动神奇子弹命中靶点的力量:重新审视热力学在药物设计、开发和优化中的作用
Life (Basel). 2022 Sep 15;12(9):1438. doi: 10.3390/life12091438.
4
Design, Cytotoxicity and Antiproliferative Activity of 4-Amino-5-methyl-thieno[2,3-d]pyrimidine-6-carboxylates against MFC-7 and MDA-MB-231 Breast Cancer Cell Lines.4-氨基-5-甲基噻吩[2,3-d]嘧啶-6-羧酸酯类化合物的设计、细胞毒性及对 MCF-7 和 MDA-MB-231 乳腺癌细胞系的增殖抑制活性。
Molecules. 2022 May 21;27(10):3314. doi: 10.3390/molecules27103314.
5
Computational Study on Potential Novel Anti-Ebola Virus Protein VP35 Natural Compounds.潜在新型抗埃博拉病毒蛋白VP35天然化合物的计算研究
Biomedicines. 2021 Nov 30;9(12):1796. doi: 10.3390/biomedicines9121796.
6
Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies.基于靶点的“类药性”性质和配体效率评价。
J Med Chem. 2021 Jun 10;64(11):7210-7230. doi: 10.1021/acs.jmedchem.1c00416. Epub 2021 May 13.
7
Theoretical Evaluation of Novel Thermolysin Inhibitors from . Possible Antibacterial Agents.新型糜蛋白酶抑制剂的理论评估:潜在的抗菌剂。
Molecules. 2021 Jan 13;26(2):386. doi: 10.3390/molecules26020386.
8
Rethinking drug design in the artificial intelligence era.人工智能时代的药物设计再思考。
Nat Rev Drug Discov. 2020 May;19(5):353-364. doi: 10.1038/s41573-019-0050-3. Epub 2019 Dec 4.
9
The nature of ligand efficiency.配体效率的本质。
J Cheminform. 2019 Jan 31;11(1):8. doi: 10.1186/s13321-019-0330-2.
10
Beware of ligand efficiency (LE): understanding LE data in modeling structure-activity and structure-economy relationships.谨防配体效率(LE):理解结构-活性和结构-经济性关系建模中的LE数据。
J Cheminform. 2017 Sep 11;9(1):49. doi: 10.1186/s13321-017-0236-9.
ACS Med Chem Lett. 2014 May 9;5(6):616-8. doi: 10.1021/ml500146d. eCollection 2014 Jun 12.
4
Improving the plausibility of success with inefficient metrics.用低效的指标提高成功的可信度。
ACS Med Chem Lett. 2013 Nov 21;5(1):2-5. doi: 10.1021/ml4004638. eCollection 2014 Jan 9.
5
Alternative variables in drug discovery: promises and challenges.药物研发中的替代变量:前景与挑战
Future Med Chem. 2014 Apr;6(5):577-93. doi: 10.4155/fmc.14.16.
6
Fragment-based lead discovery and design.基于片段的先导化合物发现与设计
J Chem Inf Model. 2014 Mar 24;54(3):693-704. doi: 10.1021/ci400731w. Epub 2014 Feb 19.
7
The role of ligand efficiency metrics in drug discovery.配体效率指标在药物发现中的作用。
Nat Rev Drug Discov. 2014 Feb;13(2):105-21. doi: 10.1038/nrd4163.
8
The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations.亲脂效率(LipE)在焓优化中应用的热力学基础。
Bioorg Med Chem Lett. 2013 Nov 1;23(21):5992-6000. doi: 10.1016/j.bmcl.2013.08.030. Epub 2013 Aug 14.
9
Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters.在分子优化中设定预期:常用综合参数的优缺点。
Bioorg Med Chem Lett. 2013 Nov 1;23(21):5980-91. doi: 10.1016/j.bmcl.2013.08.029. Epub 2013 Aug 13.
10
Automated molecule editing in molecular design.分子设计中的自动化分子编辑。
J Comput Aided Mol Des. 2013 Aug;27(8):655-64. doi: 10.1007/s10822-013-9676-0. Epub 2013 Sep 4.